Literature DB >> 12351627

Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells.

Begona Comin-Anduix1, Laszlo G Boros, Silvia Marin, Joan Boren, Carles Callol-Massot, Josep J Centelles, Josep L Torres, Neus Agell, Sara Bassilian, Marta Cascante.   

Abstract

The fermented extract of wheat germ, trade name Avemar, is a complex mixture of biologically active molecules with potent anti-metastatic activities in various human malignancies. Here we report the effect of Avemar on Jurkat leukemia cell viability, proliferation, cell cycle distribution, apoptosis, and the activity of key glycolytic/pentose cycle enzymes that control carbon flow for nucleic acid synthesis. The cytotoxic IC(50) concentration of Avemar for Jurkat tumor cells is 0.2 mg/ml, and increasing doses of the crude powder inhibit Jurkat cell proliferation in a dose-dependent fashion. At concentrations higher than 0.2 mg/ml, Avemar inhibits cell growth by more than 50% (72 h of incubation), which is preceded by the appearance of a sub-G(1) peak on flow histograms at 48 h. Laser scanning cytometry of propidium iodide- and annexin V-stained cells indicated that the growth-inhibiting effect of Avemar was consistent with a strong induction of apoptosis. Inhibition by benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone of apoptosis but increased proteolysis of poly(ADP-ribose) indicate caspases mediate the cellular effects of Avemar. Activities of glucose-6-phosphate dehydrogenase and transketolase were inhibited in a dose-dependent fashion, which correlated with decreased (13)C incorporation and pentose cycle substrate flow into RNA ribose. This decrease in pentose cycle enzyme activities and carbon flow toward nucleic acid precursor synthesis provide the mechanistic understanding of the cell growth-controlling and apoptosis-inducing effects of fermented wheat germ. Avemar exhibits about a 50-fold higher IC(50) (10.02 mg/ml) for peripheral blood lymphocytes to induce a biological response, which provides the broad therapeutic window for this supplemental cancer treatment modality with no toxic effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351627     DOI: 10.1074/jbc.M206150200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Authors:  Miriam Zanuy; Antonio Ramos-Montoya; Oscar Villacañas; Nuria Canela; Anibal Miranda; Esther Aguilar; Neus Agell; Oriol Bachs; Jaime Rubio-Martinez; Maria Dolors Pujol; Wai-Nang P Lee; Silvia Marin; Marta Cascante
Journal:  Metabolomics       Date:  2011-07-08       Impact factor: 4.290

2.  Mechanism of the anti-angiogenic effect of Avemar on tumor cells.

Authors:  Nilüfer Gülmen Imir; Esra Aydemir; Ece Şimşek
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

3.  Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity.

Authors:  Patricia L Judson; Entidhar Al Sawah; Douglas C Marchion; Yin Xiong; Elona Bicaku; Nadim Bou Zgheib; Hye Sook Chon; Xiaomang B Stickles; Ardeshir Hakam; Robert M Wenham; Sachin M Apte; Jesus Gonzalez-Bosquet; Dung-Tsa Chen; Johnathan M Lancaster
Journal:  Int J Gynecol Cancer       Date:  2012-07       Impact factor: 3.437

4.  Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2.

Authors:  Leta K Nutt; Seth S Margolis; Mette Jensen; Catherine E Herman; William G Dunphy; Jeffrey C Rathmell; Sally Kornbluth
Journal:  Cell       Date:  2005-10-07       Impact factor: 41.582

5.  The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.

Authors:  Begoña Comin-Anduix; Thinle Chodon; Hooman Sazegar; Douglas Matsunaga; Stephen Mock; Jason Jalil; Helena Escuin-Ordinas; Bartosz Chmielowski; Richard C Koya; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

6.  Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Authors:  Jonas N Søndergaard; Ramin Nazarian; Qi Wang; Deliang Guo; Teli Hsueh; Stephen Mok; Hooman Sazegar; Laura E MacConaill; Jordi G Barretina; Sarah M Kehoe; Narsis Attar; Erika von Euw; Jonathan E Zuckerman; Bartosz Chmielowski; Begoña Comin-Anduix; Richard C Koya; Paul S Mischel; Roger S Lo; Antoni Ribas
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531

Review 7.  Bioactive food components and cancer-specific metabonomic profiles.

Authors:  Young S Kim; John A Milner
Journal:  J Biomed Biotechnol       Date:  2010-11-11

8.  Dynamic profiling of the glucose metabolic network in fasted rat hepatocytes using [1,2-13C2]glucose.

Authors:  Silvia Marin; W-N Paul Lee; Sara Bassilian; Shu Lim; Laszlo G Boros; Josep J Centelles; Josep Maria FernAndez-Novell; Joan J Guinovart; Marta Cascante
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

9.  Fermented wheat germ extract--nutritional supplement or anticancer drug?

Authors:  Thomas Mueller; Wieland Voigt
Journal:  Nutr J       Date:  2011-09-05       Impact factor: 3.271

10.  Promising cytotoxic activity profile of fermented wheat germ extract (Avemar®) in human cancer cell lines.

Authors:  Thomas Mueller; Karin Jordan; Wieland Voigt
Journal:  J Exp Clin Cancer Res       Date:  2011-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.